6 While much of the emphasis in discussions about personalized medicine has been focused on http://www.selleckchem.com/products/Bosutinib.html medical technologies, aspects of information technology are becoming their equal in enabling individualization or mass customization of health care schemes. This is not unlike the disruptive innovation qualities that http://www.selleckchem.com/products/brefeldin-a.html computers have had in other industries, and will likely lead to wide-ranging and equally disruptive change for the medical community.7 One key characteristic Inhibitors,research,lifescience,medical of change will be the blurring of the lines between the established medical community, the patient/consumer, and other community members “linked”
by information systems. In the future, personalized health care will represent an amalgam of patient experiences
that will be customized, interactive, less episodic in nature, and more of a continuum of care. There will be many challenges ahead, in order for this model to be accepted and demonstrated to provide Inhibitors,research,lifescience,medical a higher quality of care, greater understanding by patients of their condition and health care choices, and improved efficiency and effectiveness of health care practices. Key catalysts on the pathways to personalized medicine The pace Inhibitors,research,lifescience,medical at which discovery research in human genomics enters translational research may be a trajectory unlike past novel interventions. In looking at personalized medicine through the lens of clinically meaningful impact, it is worthwhile to provide a context for some of the forces at play in creating the foundation for personalized medicine. Genomic sequencing and related analytic Inhibitors,research,lifescience,medical platform technologies The establishment of the public domain as the key reference source for the Human Genome Project opened the door to discovery
research that continues to pay dividends in advancing scientific frontiers. Additionally the substantial investments in large-scale science included funding for technology Inhibitors,research,lifescience,medical platforms and Entinostat their applications in the project itself. As a consequence, there was a surge in the development of sequencing technologies yielding remarkably higher throughput, dramatically reduced costs, and greatly enhanced analytic capabilities. Government-supported incentives for technology development created an economically feasible environment that has expanded genome-scale research capabilities from large sequencing centers to the laboratory bench, and now, virtual discovery research through computational analysis. These efforts were first engaged to sequence targeted regions of the genome, in order to understand polymorphisms in genes and their contribution to genetic disorders.